Evotec SE (EVO) Stock

About Evotec SE

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Evotec SE is headquartered in DE.

Evotec SE (EVO) stock trades at $2.01 with a market capitalization of $713.93M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.26, reflecting a net loss over the last twelve months, price-to-book of 0.90, price-to-sales of 0.84. Over the past 52 weeks the stock has ranged between $1.97 and $4.42, and currently trades 54.5% below its 52-week high.

On profitability, Evotec SE generates a return on equity (ROE) of -24.55% (negative, reflecting a net loss), return on capital employed of -8.50%, an operating margin of -13.88%, a net profit margin of -26.02%.

Official website: www.evotec.com

Evotec SE by the numbers, 2016–2025

Between 2016 and 2025 Evotec SE reported revenue of $165.0M rising to $757.0M, a change of +358.8% across 10 years. Compounded, revenue has grown 8.6% a year over five years, 0.3% over three, -5.0% over the last twelve months. Net profit fell to $-99.0M.

Operating margin went from 19.1% in 2016 to -17.9% in 2025, a fall of 36.9 percentage points. The most recent net margin is -26.02%. On a trailing twelve-month basis to Mar '26, revenue is $745.0M and net profit $-196.0M.

Borrowings rose from $29.0M to $447.0M, cash on hand is $445.2M, cash from operations was $-9.0M in the latest year, positive in 9 of the last 10.

Return on equity has averaged -7.9% over five years, and was -12.2% in the most recent year.

The share price itself has compounded at -37.3% a year over five years, -45.4% over three, -52.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Evotec SE (EVO) — frequently asked questions